EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 41 / No 1 (March 2009) J Extra Corpor Technol, 41 1 (2009) 32-36 References
Free Access
Issue
J Extra Corpor Technol
Volume 41, Number 1, March 2009
Page(s) 32 - 36
DOI https://doi.org/10.1051/ject/200941032
Published online 15 March 2009
  1. Yusef S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. [CrossRef] [PubMed] [Google Scholar]
  2. Steinhubl S, Berger PB, Mann JTIII, et al. CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20. [CrossRef] [PubMed] [Google Scholar]
  3. Burns T, Moss A, Hilleman D. Antiplatlet drug resistance: not ready for prime time. Pharmacotherapy. 2005;25:1621–18. [CrossRef] [PubMed] [Google Scholar]
  4. Michaelson A. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:489–493. [Google Scholar]
  5. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular event. Circulation. 2002;105:1650–5. [CrossRef] [PubMed] [Google Scholar]
  6. Matekzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–5. [Google Scholar]
  7. Steinhubl S, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multi-center study. Circulation. 2001;103:2572–8. [Google Scholar]
  8. US Food and Drug Administration. FDA news “FDA Approves Drug-Eluting Stent for Clogged Heart Arteries” 24 April 2003. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00896.html Accessed December 2005. [Google Scholar]
  9. The Lancet CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patents at risk of ischaemic events (CAPRIE). Lancet. 1996;348:11329–39. [Google Scholar]
  10. Clark TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53–9. [CrossRef] [PubMed] [Google Scholar]
  11. Mukherjee D, Line-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005;91:23–6. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.